Table 2.
Primers used in this study for amplification of the respective targeted genes.
| Gene | Accession number | Sequence (5′-3′) | Location | Expectedsize (bp) |
|---|---|---|---|---|
| BEFV M | AF234533 | F: GAGATGGTTACCCTTTTCAAGAAA GG R: TCATGACTTAACTAAGTTAGTGAAACCATG |
1–23 672–643 |
672 |
| ULK1 | NM_001205927 | F: AAGGGCAGCGCCAGCGAGG R: CGTCCGCCTGGTCCGTGA |
2605–2623 3094–3077 |
490 |
| ATG7 | NM_001142967 | F: ATGGCCTTTGAGGAACCTTT R: ATGCCTCCCTTCTGGTTCTT |
726–745 935–916 |
210 |
| LC3B | NM_001001169 | F: ATGCCGTCCGAGAAAACCTT R: TTACACAGATAATTTCATTCC |
1–20 378–358 |
378 |
| GAPDH | NM-001034034 | F: CAAGGTCATCCATGACAACTTTG R: GTCCACCACCCTGTTGCTGTAG |
477–499 972–951 |
496 |